Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,140 matching trials from the live ClinicalTrials.gov search.
Not listed Not applicable Interventional Accepts healthy volunteers

Rapid Vaccination of Hard-To-Reach Populations

NCT00155974
Conditions
Influenza
Interventions
Community-based vaccine outreach intervention
Biological
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
18
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 14 more
Conditions
Influenza
Interventions
LAIV, Saline
Biological · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Panbio™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
Not listed
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Easley, South Carolina
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Defense Protein Impact On Respiratory Immune Outcomes

NCT07431840
Conditions
Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions
Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo
Dietary Supplement
Lead sponsor
Quantec Ltd
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Healthy, Gastrointestinal Dysfunction, Cold Symptom, Flu Symptom
Interventions
Whole Cell Algae Fermentate, Placebo
Dietary Supplement
Lead sponsor
Kemin Foods LC
Industry
Eligibility
21 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Addison, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gene Signatures of Influenza Vaccine Responses in Older Adults

NCT03603509
Conditions
Influenza
Interventions
Fluad Vaccine, Fluzone High-Dose
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers

Testing a Personally Controlled Health Record to Ameliorate Influenza at MIT

NCT00531700
Conditions
Influenza
Interventions
Health messaging, Health messages
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Immune Response to Seasonal FluMist in Healthy Adults

NCT01673425
Conditions
Influenza
Interventions
Live Attenuated Influenza Vaccine
Drug
Lead sponsor
National Center for Occupational Health and Infection Control
Federal
Eligibility
20 Years to 49 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluzone
Biological
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Influenza A Virus, H1N1 Subtype
Interventions
Zanamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

NCT06436703
Conditions
Influenza, Human
Interventions
Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
32
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 25 more
Conditions
Influenza
Interventions
QIVc, TIV1c, TIV2c
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years and older
Enrollment
2,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 33 more
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Adults

NCT01938742
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Decatur, Georgia • Iowa City, Iowa • Cincinnati, Ohio + 1 more
Conditions
Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
Interventions
Not listed
Lead sponsor
IQuum, Inc.
Industry
Eligibility
Not listed
Enrollment
1,642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Delray Beach, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more
Conditions
Influenza Infection
Interventions
VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Pregnancy
Interventions
Tetanus, Diphtheria, and Pertussis Vaccine, 2016-2017 Quadrivalent Inactivated Influenza Vaccine, 2017-2018 Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio
Conditions
Influenza
Interventions
Peramivir, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
0 Days to 17 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Shreveport, Louisiana • Dayton, Ohio • Smithfield, Pennsylvania + 6 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more
Conditions
Avian Influenza
Interventions
AS03, MF59, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
7
States / cities
Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally

NCT00436046
Conditions
Influenza
Interventions
Trivalent inactivated influenza virus vaccine (2006-2007 formulation), Type 1 interferon
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

NCT01310413
Conditions
Influenza, Influenza Vaccines
Interventions
Influenza A (H5N1) Virus monovalent vaccine, Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
842 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
11
States / cities
Paramount, California • Sacramento, California • Newton, Kansas + 8 more
Conditions
Hematologic Malignancy, Pediatric Cancer, Transplant-Related Cancer
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

NCT01698060
Conditions
Avian Influenza
Interventions
ND1.1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky